Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The US$474m market-cap company posted a loss in its most recent financial year of US$93m and a latest trailing-twelve-month loss of US$61m shrinking the gap between loss and breakeven. The most pressing concern for investors is Theravance Biopharma's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company. Check out our latest analysis for Theravance Biopharma Theravance Biopharma is bordering on breakeven, according to the 4 American Pharmaceuticals analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$54m in 2026. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Worki
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma, Inc. (NASDAQ: TBPH) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.MarketBeat
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 [YahooYahoo
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024PR Newswire
- Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
TBPH
Earnings
- 2/26/24 - Miss
TBPH
Sec Filings
- 4/5/24 - Form DEF
- 4/4/24 - Form 4
- 4/4/24 - Form 4
- TBPH's page on the SEC website